Manufacturing of new formulations of Isosorbide dinitrate by direct compression method and their comparative evaluation with different brands available in the market
Author(s)
Huma Dilshad , Safila Naveed ,
Download Full PDF Pages: 81-88 | Views: 845 | Downloads: 200 | DOI: 10.5281/zenodo.3411908
Abstract
The aim of this study was to develop new formulations of Isosorbide dinitrate by direct compression method using Talc instead of magnesium stearate. The present study is divided into two phases. In the first phase new formulation of Isosorbide dinitrate was prepared by direct compression method and during manufacturing magnesium stearate was replaced by Talc as it is cheaper, less process dependant and requires less blending time as compared to magnesium stearate. Blending time differences of as little as two minutes can significantly alter the dissolution pattern of finished tablets. In the 2nd phase three different brands of isosorbide dinitrate tablets were randomly selected from the local market using probability sampling tools and evaluated for weight variation, hardness, friability, disintegration, dissolution (by using HPLC). Pharmaceutical assays (by using spectrophotometer and HPLCr) were also conducted according to the methods and guidelines given in BP/USP. The results showed that all parameters (weight-variation, thickness, hardness, friability, disintegration, dissolution and Pharmaceutical assays of new formulations are in accordance with the BP/USP limits and the new formulation containing talc showed better potency as compared to other market brands. The most obvious advantage of replacement of magnesium stearate by talc is its better economy, owing to reduce processing time, less equipment and space required less process validation and lower energy utilization with equal potency and safety.
Keywords
ISDN (Isosorbide dinitrate), Talc, Mg-Stearate, Friability, Disintegration, Dissolution, Pharmaceutical Assay.
References
i. Akhavan J., The Chemistry of Explosives, 2th ed, RSC Publishing, Cambridge. (2004); 2: 125-137.
ii. Agrawal J.P., Hodgson R., Organic Chemistry of Explosives, Wiley Intersci., N.Y. (2007);13: 87-98
iii. Livertoux L.H., Lagrange P., Mina A., The Superoxide Production Mediated by the Redox Cycling of Xenobiotics in Rat Brain Microsomes is Dependent on Their Reduction Potential. Brain Res. (1996); 725:207-216.
iv. Marsh N., Marsh A. A Short History of Nitroglycerine and Nitric Oxide in Pharmacology and Physiology. Clin. Exp. Pharmacol. Physiol. (2000); 27(4): 313-319.
v. Fox K., Garcia M.A.A., Ardissino D. et al. Guidelines on the Management of Stable Angina Pectoris, Europ. Heart J. (2006); 27 : 1341-81.
.vi. Abraham D.J. (Ed.) Cardiovascular Agents and Endocrines, in: Burger’s Medicinal Chemistry and Drug Discovery, Wiley-Intersci., N.Y., (2003); 3: 111-134.
vii. Sam, A.P., Fokkens, J.G., Drug Delivery System, Adding Therapeutic and Economic value to Pharmacotherapy, Pharm. Tech. Eur.(1997); 9: 58-66.
viii. Rasenack N, Muller BW. Crystal Habit and Tableting Behaviour. Int.. J. Pharm.(2002); 244:45-57.
ix. Khan KA, Rhodes CT. The Production of Tablets by Direct Compression. Can. J. Pharm. Sci.(1973); 8: 1-5.
x. Robertson MI. Regulatory Issue with Excipients. Int. J. Pharm.(1999); 197: 273-276
xi. Shangraw RF, Demarets DA. Survey of Current Particles in the Formulation and Manufacture of tablets and Capsules. Pharm. Technol (1993); 17: 32-44.
xii. Aulton M.E. The science of dosage form design. Churchill Livingstone Edinburgh London. Melbourne and New York .(1988):662.
xiii. Mittal C K, Murad F. Guanylate Cyclase, regulation of cyclic GMP metabolism .Hand book of experimental pharmacology. Springer –verlag. (1982);58:225-260
xiv. Dollery Colin S, Therapeutic Drugs . Churchill LivingstoneEdinburgh London. 1991;1:1104
xv. Edward M Rudnic , Joseph B Schwartz.. Oral Solid Dosage Forms. Remington: The Science And Practice Of Pharmacy –(2006): pp 890 .Maryland USA
xvi. Nutter –Smith, A.New instrument and method for evaluating tablet fracture resistance. Journal of Pharmaceutical sciences . 1961;163: 194 -195
.
xvii. United states pharmacopoeia (USP 23,NF(1995)PP:1790).Published by United States Pharmacopoeial Convention,Inc.12601Twinbrook parkway, Rockvill, MD 20852.
Cite this Article: